Vasomotor Symptoms of Menopause - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Vasomotor Symptoms of Menopause - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Vasomotor Symptoms of Menopause - Pipeline Review, H2 2014', provides an overview of the Vasomotor Symptoms of Menopause's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasomotor Symptoms of Menopause, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasomotor Symptoms of Menopause and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vasomotor Symptoms of Menopause and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vasomotor Symptoms of Menopause products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasomotor Symptoms of Menopause pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasomotor Symptoms of Menopause
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vasomotor Symptoms of Menopause Overview 6
Therapeutics Development 7
Pipeline Products for Vasomotor Symptoms of Menopause - Overview 7
Pipeline Products for Vasomotor Symptoms of Menopause - Comparative Analysis 8
Vasomotor Symptoms of Menopause - Therapeutics under Development by Companies 9
Vasomotor Symptoms of Menopause - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Unknown Stage Products 12
Vasomotor Symptoms of Menopause - Products under Development by Companies 13
Vasomotor Symptoms of Menopause - Companies Involved in Therapeutics Development 14
Arbor Pharmaceuticals, LLC. 14
Ausio Pharmaceuticals, LLC 15
Edgemont Pharmaceuticals, LLC 16
EndoCeutics, Inc. 17
Pantarhei Bioscience BV 18
Pfizer Inc. 19
Vasomotor Symptoms of Menopause - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 29
(bazedoxifene acetate + conjugated estrogens) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(estrogen + progesterone) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
(prasterone + acolbifene) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AR-08 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AUS-131 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EDG-007 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Vasomotor Symptoms of Menopause - Recent Pipeline Updates 38
Vasomotor Symptoms of Menopause - Discontinued Products 40
Vasomotor Symptoms of Menopause - Product Development Milestones 41
Featured News & Press Releases 41
Oct 03, 2013: Pfizer Announces FDA Approval Of DUAVEE For The Treatment Of Moderate-To-Severe Vasomotor Symptoms Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis 41
Dec 13, 2012: Pfizer And Ligand Pharma Announce FDA Acceptance Of New Drug Application For Bazedoxifene/Conjugated Estrogens 42
Jul 19, 2012: EMA Accepts Regulatory Submission For Pfizer's Bazedoxifene/Conjugated Estrogens For Treatment Of Symptoms Associated With Menopause And Osteoporosis 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products under Development for Vasomotor Symptoms of Menopause, H2 2014 7
Number of Products under Development for Vasomotor Symptoms of Menopause - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Vasomotor Symptoms of Menopause - Pipeline by Arbor Pharmaceuticals, LLC., H2 2014 14
Vasomotor Symptoms of Menopause - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 15
Vasomotor Symptoms of Menopause - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2014 16
Vasomotor Symptoms of Menopause - Pipeline by EndoCeutics, Inc., H2 2014 17
Vasomotor Symptoms of Menopause - Pipeline by Pantarhei Bioscience BV, H2 2014 18
Vasomotor Symptoms of Menopause - Pipeline by Pfizer Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Assessment by Combination Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 28
Vasomotor Symptoms of Menopause Therapeutics - Recent Pipeline Updates, H2 2014 38
Vasomotor Symptoms of Menopause - Discontinued Products, H2 2014 40